You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥-B(06996.HK)2021年實現營收2876.9萬元 研發開支提升至4.05億元
格隆匯 03-18 13:37

格隆匯3月18日丨德琪醫藥-B(06996.HK)公佈2021年度業績,集團實現收入2876.9萬元人民幣(單位下同),而去年則無營收,主要歸因於指定患者用藥計劃收入增加;其他收入及收益 4256.7萬元,同比增長58.6%,主要歸因於政府補助及銀行利息收入增加。

集團的研發成本從截至2020年12月31日止年度的3.48億元增加5730萬元至截至2021年12月31日止年度的4.05億元,主要歸因於集團藥物研發開支增加及研發人員擴張,部分被集團的許可費及以權益結算的購股權開支減少所抵銷。

集團已戰略性地設計並組建起一條擁有15款腫瘤藥物資產的創新型研發管線,其中5款為亞太權益,另10款藥物擁有全球權益。集團採用”組合、互補“的研發策略,最大限度地發揮可相互協同的管線資產的潛力。集團於六大亞太地區市場(包括中國內地、韓國、澳大利亞、新加坡、香港及台灣)的衞生主管部門已提交selinexor的NDA,並已獲得中國內地、韓國、新加坡及澳大利亞的NDA批准。

集團還針對集團的主要產品selinexor在中國內地用於治療復發╱難治性多發性骨髓瘤、復發╱難治性瀰漫大B細胞淋巴瘤、子宮內膜癌及骨髓纖維化癌獲得了IND批准或啟動了五項註冊性臨牀試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account